
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
Details
More Products & Services
People

Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience

Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery

Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients

Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Treatment strategy combines gilteritinib & FLT3 CAR T cells
- Enhanced and sustained anti-leukemia activity seen vs. monotherapy
- Gilteritinib could also boost effectiveness of other CAR T-cell immunotherapies
- Treatment strategy combines gilteritinib & FLT3 CAR T cells
- Enhanced and sustained anti-leukemia activity seen vs. monotherapy
- Gilteritinib could also boost effectiveness of other CAR T-cell immunotherapies

Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link